<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39446792</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.</ArticleTitle><Pagination><StartPage>e0309449</StartPage><MedlinePgn>e0309449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0309449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0309449</ELocationID><Abstract><AbstractText>COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = &lt;0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright: © 2024 Iasella et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iasella</LastName><ForeName>Carlo J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-2668-3570</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannan</LastName><ForeName>Stefanie J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieber</LastName><ForeName>Sophia C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Antu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Dimiter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medicine, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saul</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6712-5102</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>Iulia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koshy</LastName><ForeName>Ritchie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lape</LastName><ForeName>Braidon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sembrat</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devonshire</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitsios</LastName><ForeName>Georgios D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinidis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6785-1318</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bill B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlo</LastName><ForeName>Christian A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hager</LastName><ForeName>David N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pathology, Division of Transfusion Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazer</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Division of Transfusion Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Alan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Division of Laboratory Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVerry</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>Darrell J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Division of Transfusion Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDyer</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39446792</ArticleId><ArticleId IdType="pmc">PMC11500870</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0309449</ArticleId><ArticleId IdType="pii">PONE-D-24-08307</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130: 1545–1548. doi: 10.1172/JCI138003</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138003</ArticleId><ArticleId IdType="pmc">PMC7108922</ArticleId><ArticleId IdType="pubmed">32167489</ArticleId></ArticleIdList></Reference><Reference><Citation>EUA 26382 COVID-19 Convalescent Plasma. In: US Food and Drug Administration [Internet]. Aug 2020 [cited 22 Mar 2023]. Available: https://www.fda.gov/media/141480/download.</Citation></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al.. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397: 2049–2059. doi: 10.1016/S0140-6736(21)00897-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00897-7</ArticleId><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371. doi: 10.1136/bmj.m3939</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3939</ArticleId><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, De Molina RM, Torres F, et al.. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131. doi: 10.1172/JCI152740</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI152740</ArticleId><ArticleId IdType="pmc">PMC8516461</ArticleId><ArticleId IdType="pubmed">34473652</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al.. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA—J Am Med Assoc. 2020;324. doi: 10.1001/jama.2020.10044</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al.. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021;384. doi: 10.1056/NEJMoa2033700</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al.. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med. 2022;386: 1700–1711. doi: 10.1056/NEJMoa2119657</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119657</ArticleId><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al.. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6: e2250647–e2250647. doi: 10.1001/jamanetworkopen.2022.50647</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.50647</ArticleId><ArticleId IdType="pmc">PMC9857047</ArticleId><ArticleId IdType="pubmed">36633846</ArticleId></ArticleIdList></Reference><Reference><Citation>Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al.. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021;385: 1951–1960. doi: 10.1056/NEJMoa2103784</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103784</ArticleId><ArticleId IdType="pmc">PMC8385553</ArticleId><ArticleId IdType="pubmed">34407339</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, et al.. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022;10: 278–288. doi: 10.1016/S2213-2600(21)00545-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00545-2</ArticleId><ArticleId IdType="pmc">PMC8828369</ArticleId><ArticleId IdType="pubmed">35150610</ArticleId></ArticleIdList></Reference><Reference><Citation>National COVID Cohort Collaborative. In: National Center for Advancing Translational Sciences, National Institutes of Health [Internet].
2022.  [cited 6 Jul 2023]. Available: https://ncats.nih.gov/n3c/about/data-overview.</Citation></Reference><Reference><Citation>Li W, Schä A, Kulkarni SS, Liu X, Martinez DR, Chen C, et al.. High Potency of a Bivalent Human V H Domain in SARS-CoV-2 Animal Models In Brief High Potency of a Bivalent Human V H Domain in SARS-CoV-2 Animal Models. Cell. 2020;183: 429–441. doi: 10.1016/j.cell.2020.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.007</ArticleId><ArticleId IdType="pmc">PMC7473018</ArticleId><ArticleId IdType="pubmed">32941803</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al.. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5: 8413. doi: 10.1126/sciimmunol.abc8413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc8413</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A, et al.. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nat 2021 5977874. 2021;597: 97–102. doi: 10.1038/s41586-021-03807-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03807-6</ArticleId><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, et al.. Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin Proc Innov Qual Outcomes. 2023;7: 499–513. doi: 10.1016/J.MAYOCPIQO.2023.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MAYOCPIQO.2023.09.001</ArticleId><ArticleId IdType="pmc">PMC10582279</ArticleId><ArticleId IdType="pubmed">37859995</ArticleId></ArticleIdList></Reference><Reference><Citation>Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al.. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021;385: 1951–1960. doi: 10.1056/NEJMoa2103784</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103784</ArticleId><ArticleId IdType="pmc">PMC8385553</ArticleId><ArticleId IdType="pubmed">34407339</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine AC, Fukuta Y, Huaman MA, Ou J, Meisenberg BR, Patel B, et al.. Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials. Clin Infect Dis. 2023;76: 2077–2086. doi: 10.1093/cid/ciad088</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad088</ArticleId><ArticleId IdType="pmc">PMC10273382</ArticleId><ArticleId IdType="pubmed">36809473</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al.. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021;385: e81. doi: 10.1056/NEJMoa2108163</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable RR, Pawlowski C, O’Horo JC, Arndt LL, Arndt R, Bierle DM, et al.. Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. eClinicalMedicine. 2021;40: 101102. doi: 10.1016/j.eclinm.2021.101102</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101102</ArticleId><ArticleId IdType="pmc">PMC8404031</ArticleId><ArticleId IdType="pubmed">34485873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginde AA, Paredes R, Murray TA, Engen N, Grandits G, Vekstein A, et al.. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022;10: 972–984. doi: 10.1016/S2213-2600(22)00215-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00215-6</ArticleId><ArticleId IdType="pmc">PMC9270059</ArticleId><ArticleId IdType="pubmed">35817072</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al.. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet (London, England). 2021;397: 2049–2059. doi: 10.1016/S0140-6736(21)00897-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00897-7</ArticleId><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton FW, Lee T, Arnold DT, Lilford R, Hemming K. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int J Infect Dis. 2021;109: 114–117. doi: 10.1016/j.ijid.2021.06.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.06.034</ArticleId><ArticleId IdType="pmc">PMC8214317</ArticleId><ArticleId IdType="pubmed">34157385</ArticleId></ArticleIdList></Reference><Reference><Citation>Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al.. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2022;4. doi: 10.1038/s43018-022-00503-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-022-00503-w</ArticleId><ArticleId IdType="pmc">PMC9886549</ArticleId><ArticleId IdType="pubmed">36581734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al.. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19. Blood. 2020;136: 2290–2295. doi: 10.1182/blood.2020008423</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008423</ArticleId><ArticleId IdType="pmc">PMC7702482</ArticleId><ArticleId IdType="pubmed">32959052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, et al.. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131. doi: 10.1172/JCI155114</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI155114</ArticleId><ArticleId IdType="pmc">PMC8670841</ArticleId><ArticleId IdType="pubmed">34788233</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, et al.. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022;59. doi: 10.1183/13993003.01724-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01724-2021</ArticleId><ArticleId IdType="pmc">PMC8576805</ArticleId><ArticleId IdType="pubmed">34446469</ArticleId></ArticleIdList></Reference><Reference><Citation>Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al.. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021;131. doi: 10.1172/JCI152264</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI152264</ArticleId><ArticleId IdType="pmc">PMC8516466</ArticleId><ArticleId IdType="pubmed">34464358</ArticleId></ArticleIdList></Reference><Reference><Citation>Merin NM, LeVee AA, Merlo CA, Spector K, Coleman H, Klapper E, et al.. The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study. Transfus Apher Sci. 2022;61: 103423. doi: 10.1016/j.transci.2022.103423</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2022.103423</ArticleId><ArticleId IdType="pmc">PMC8923025</ArticleId><ArticleId IdType="pubmed">35337753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>